X

Trial Profile

Telavancin Observational Use Registry (TOUR)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telavancin (Primary)
Indications Bacteraemia; Bone and joint infections; Endocarditis; Gram-positive infections; Nosocomial pneumonia; Skin and soft tissue infections; Staphylococcal infections
Focus Therapeutic Use
Acronyms TOUR
Sponsors Cumberland Pharmaceuticals; Theravance Biopharma

Most Recent Events

26 May 2020 Results of sub analysis (n=151) from this TOUR is published in the Cumberland Pharmaceuticals Inc Media Release
05 May 2020 Results published in a new publication in Drugs - Real World Outcomes journal
08 Oct 2018 Results presented in the Theravance Biopharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com